Between 2011 and 2013, the proportion of men diagnosed with intermediate- or high-risk prostate cancer, increased by 3% per year. Thank you members of the United States Preventive Services Task Force for realy blowing it and tapping in the nail into the coffins of American men. In a preliminary study the authors estimate that this [...]
There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac has unoffically let it been known that Prostvac when combined with another investigational immunologic therapy, Yervoy, has helped to significantly [...]
Chemotherapy for prostate cancer is still limited to just two drugs, docetaxel (Taxotere) and cabazitaxel (Jevtana). Both of these chemotherapy drugs are taxanes, but they seem to be very different in their mode of action. A study published online in Clinical Cancer Research, indicates that cabazitaxel might be more effective for some men than docetaxel. [...]
Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month [...]
Many men with advanced prostate cancer who are on hormone therapy (ADT) use one of the newer drugs, degarelix (Firmagon) to achieve a state of castration. Degarelix is considered a superior drug for initiating ADT because it is not accompanied with a PSA flare that is common with the older luteinizing hormone-releasing hormone (LHRH) agonists [...]